Inhibrx Set to Share Ozekibart Data in Late-Line Colorectal Cancer Trial
Event summary
- Inhibrx to host webcast on April 21, 2026, detailing Phase 1/2 data for ozekibart (INBRX-109) in combination with FOLFIRI for late-line colorectal cancer.
- Ozekibart previously demonstrated significant PFS benefit in chondrosarcoma trial (ChonDRAgon), reducing risk of progression/death by 52% vs. placebo.
- Company restructured in January 2024 following Sanofi acquisition of INBRX-101 program, now focusing on ozekibart and INBRX-106 pipeline.
The big picture
Inhibrx's update comes as biotech investors scrutinize pipeline diversification following Sanofi's acquisition of its flagship program. The colorectal cancer indication represents a strategic pivot toward higher-prevalence oncology targets after proving efficacy in rare diseases like chondrosarcoma, where ozekibart became the first therapy to show PFS benefit in a randomized trial.
What we're watching
- Clinical Efficacy
- Whether ozekibart's success in chondrosarcoma translates to colorectal cancer, a larger market opportunity.
- Regulatory Pathway
- The pace at which Inhibrx advances ozekibart through late-stage trials given prior Fast Track designation.
- Pipeline Strategy
- How Inhibrx balances focus between ozekibart and INBRX-106 post-restructuring.
Our editorial coverage: